1. Lin X, Wang G, Shen S, Zhan J. Advances in the diagnosis and treatment of autism spectrum disorders in children. Altern Ther Health Med 2024;30:170-5.
2. Neama ED, AL-Azawi RSA, Ibraheem NJ, Ali NH, Abdul-Ameer BG, Chassab MK, et al. A review on autism spectrum disorder and current perspectives with future directions. Int J Autism 2024;4:24-8.
9. Bolton PF, Clifford M, Tye C, Maclean C, Humphrey A, le Marechal K, et al. Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study. Psychol Med 2015;45:2321-31.
19. Adamson LB, Bakeman R. The development of shared attention during infancy. Ann Child Dev 1991;8:1-41.
21. Kasari C, Paparella T, Freeman S, Jahromi LB. Language outcome in autism: randomized comparison of joint attention and play interventions. J Consult Clin Psychol 2008;76:125-37.
23. Mullen EM. Mullen scales of early learning. Circle Pines: American Guidance Service; 1995.
27. Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization for clinical trials. J Clin Epidemiol 1999;52:19-26.
32. Harris S, Kasari C, Sigman MD. Joint attention and language gains in children with Down syndrome. Am J Ment Retard 1996;100:608-19.
34. Luyster R. Autism diagnostic observation schedule, second edition (ADOS-2) manual (Part II): Toddler Module. Torrance: Western Psychological Services; 2012.
43. Cho J, Joo YS, Yoon JG, Lee SB, Kim SY, Chae J, et al. Characterizing families of pediatric patients with rare diseases and their diagnostic odysseys: a comprehensive survey analysis from a single tertiary center in Korea. Ann Child Neurol 2024;32:167-75.
46. Ingersoll B, Frost KM, Straiton D, Ramos AP, Casagrande K. Telehealth coaching in project ImPACT indirectly affects children's expressive language ability through parent intervention strategy use and child intentional communication: an RCT. Autism Res 2024;17:2177-87.
48. Bebin EM, Peters JM, Porter BE, McPherson TO, O'Kelley S, Sahin M, et al. Early treatment with vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex: the PREVeNT trial. Ann Neurol 2024;95:15-26.